Art

J-GLOBAL ID：201802285104555004   Reference number：18A1284627

Effectiveness of Natalizumab in Japanese Patients with Multiple Sclerosis According to Background Factors: Findings from Second Report of an Interim Analysis of the Natalizumab Post-marketing Surveillance

背景因子別にみたナタリズマブの日本人多発性硬化症に対する有効性:ナタリズマブ使用成績調査中間解析から(第二報)

Author (9)： YOKOYAMA KAZUMASA (順天堂大 医 脳神経内科) ,  SATO RYUSUKE (バイオジェン・ジャパン) ,  MAKIOKA HARUKI (バイオジェン・ジャパン) ,  IIZUKA YUKIHIKO (バイオジェン・ジャパン) ,  HASE MASAKAZU (バイオジェン・ジャパン) ,  LING Yan (バイオジェン・ジャパン) ,  TORII SHIN'ICHI (バイオジェン・ジャパン) ,  SAIDA TAKAHIKO (京都保健会 京都民医連中央病院) ,  SAIDA TAKAHIKO (関西多発性硬化症セ)
Material： 診療と新薬  (Medical Consultation & New Remedies)
Volume： 55  Issue： 6  Page： 449-456  Publication year： Jun. 28, 2018 
JST Material Number： Z0942A  ISSN： 0037-380X  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： factor ,...
Semi thesaurus term： *natalizumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1284627&from=J-GLOBAL&jstjournalNo=Z0942A") }}

JST classification (1)： Clinical application of immunotherapeutic agents and blood preparations  (GW22020O)

Reference (16)：

• Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
• Havrdova E, Galetta S, Hutchinson M, et al: Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-60.
• Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
• Butzkueven H, Kappos L, Pellegrini F, et al; TYSABRI Observational Program (TOP) Investigators: Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85: 1190-7.
• Saida T, Kira JI, Kishida S, et al; Natalizumab Trial Principal Investigators : Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord 2017; 11: 25-31.

Terms in the title (7)： 背景因子 ,  ナタリズマブ ,  日本人 ,  多発性硬化症 ,  有効性 ,  使用成績調査 ,  中間解析